The US Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on...
The European Union's drugs regulator has rejected Eisai and Biogen's Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain swelling did...
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on...
Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with US-based Biogen.
The development comes after a health...
A Japanese health ministry panel on Monday recommended approval of the Alzheimer's disease treatment Leqembi, following standard approval for the drug granted by U.S....
Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to...